Glaucoma, Vision & Longevity: Supplements & Science

VisualFieldTest.com

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

  1. New Glaucoma Treatments in 2026: What Patients Should Know About Longer-Lasting Eye Pressure Control

    14H AGO

    New Glaucoma Treatments in 2026: What Patients Should Know About Longer-Lasting Eye Pressure Control

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/new-glaucoma-treatments-in-2026-what-patients-should-know-about-longer-lasting-eye-pressure-control Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: New Glaucoma Treatments for 2026: Longer-Lasting Pressure Control Glaucoma, a leading cause of vision loss, is driven by high intraocular pressure (IOP) in the eye. Daily eye drops are the main treatment, but many patients find them hard to use consistently. Drops can sting, cause redness, or simply be forgotten in the busy routines of life () (). Missing doses can let eye pressure creep up, risking vision loss. Sustained-release glaucoma treatments aim to solve this by steadily delivering medication without daily drops. Instead of an eyedrop bottle, a doctor places a tiny implant or device that continuously releases glaucoma medicine for months. These approaches remove the need to remember daily drops and help keep pressure controlled around the clock () (). Below we explain how these new treatments work, who might benefit, and how they compare to traditional drops. We focus on the options most talked about for 2026, separating those already FDA-approved from those still being studied. How Sustained-Release Treatments Work Traditional glaucoma drops deliver medication onto the eye surface, but much of it washes away before it can work. Sustained-release devices sit inside the eye or on eye tissue and let out drug slowly over time. For example, Durysta is a tiny biodegradable rod (about 1.1 mm long) that an eye doctor injects into the anterior chamber (the front part of the eye) (). It contains 10 micrograms of bimatoprost (the medicine in Lumigan drops) embedded in a dissolving polymer. Once placed, Durysta releases bimatoprost steadily for about 4–6 months () (). The implant then dissolves on its own, so no second procedure is needed. Another approach, used by iDose TR, is a tiny titanium implant anchored into the eye wall. This anchoring device contains a reservoir of travoprost (another prostaglandin drug). About 75 micrograms of travoprost continuously elutes (seeps out) into the eye through a controlled membrane (). The iDose TR device stays in place for up to 2–3 years, delivering medication 24/7. (As of early 2026, the FDA has even approved re-administering iDose TR when the first dose runs out () ().) Both Durysta and iDose TR release prostaglandin-type drugs that help fluid drain out of the eye, lowering pressure. Similarly, experimental implants like OTX-TIC (Paxtrava), PA5108, and ENV515 are designed as tiny biodegradable implants or particles that doctors insert into the eye. They work the same way: a drug (e.g. travoprost or latanoprost) is slowly released over months () (). Punctal plugs, by contrast, sit in the tear drainage ducts (near the nose) and gently release medication into the tears () (). Each system steadily bathes the eye in medicine, nearly eliminating the peaks and troughs of pressure seen with once-daily drops. Who might benefit? These devices are best for people with open-angle glaucoma or ocular hypertension who need regular IOP control but struggle with daily drops. Older patients, those with limited mobility or trouble handling eye drops, or anyone who miss doses are prime candidates () (). Because the drugs are in continuous contact with the eye, these devices often work as well as or better than drops while leav Support the show

    18 min
  2. Endothelin-1 Peptide and Glaucoma: Targeting a Problem Pathway

    4D AGO

    Endothelin-1 Peptide and Glaucoma: Targeting a Problem Pathway

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/endothelin-1-peptide-and-glaucoma-targeting-a-problem-pathway Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Endothelin-1 Peptide and Glaucoma: Targeting a Problem Pathway Glaucoma is an eye disease in which the optic nerve is damaged, often by high pressure inside the eye. Standard treatment focuses on lowering intraocular pressure (IOP). However, doctors increasingly recognize that poor blood flow and other factors also contribute to nerve damage. One molecule under study is endothelin-1 (ET-1). ET-1 is a natural peptide (small protein) made by blood vessel cells and eye tissues that is the most potent vasoconstrictor in the body (). In other words, it strongly narrows blood vessels. When ET-1 levels are high, retinal and optic nerve blood vessels can tighten, reducing oxygen and nutrients to the optic nerve. In this way, too much ET-1 may “stress” the optic nerve fibers and contribute to glaucoma damage (). In fact, many studies find ET-1 is elevated in glaucoma patients’ blood and eye fluid () (). Here we explain what ET-1 does in the eye, summarize the evidence linking ET-1 to glaucoma damage, and discuss possible treatments that block its pathway (rather than using ET-1 itself as a drug). What is Endothelin-1 and How Does It Affect the Eye? Endothelin-1 (ET-1) is made by cells lining blood vessels throughout the body, and it helps regulate normal blood pressure and flow. In the eye, ET-1 is produced in several places: the retina, the blood vessels of the eye, the retinal pigment epithelium, the optic nerve head, and the structures that make and drain fluid (aqueous humor) (). Under normal conditions, ET-1 keeps a balance: it tightens vessels when needed and releases them when other signals come in. However, ET-1 is a very powerful constrictor. Rosenthal and Fromm describe ET-1 as “the most potent vasoactive peptide known to date” (), meaning none of the body’s chemicals narrows vessels more strongly. In the eye’s tiny blood vessels, overactive ET-1 can seriously reduce blood flow. For example, if ET-1 rises, it causes vasoconstriction (narrowing) of blood vessels in the retina and optic nerve head (). This can trigger ischemia (low blood supply) in the optic nerve. Over time, that lack of oxygen and nutrients can injure or kill the retinal ganglion cells (the nerve cells in the retina whose fibers form the optic nerve). Rosenthal et al. note that such ischemia “is assumed to contribute to the degeneration of retinal ganglion cells” in glaucoma (). ET-1 also affects fluid drainage in the eye. Aqueous humor (the fluid in the eye) normally drains out through a spongy tissue called the trabecular meshwork. ET-1 makes those meshwork cells contract (), which can reduce outflow and potentially raise eye pressure. Indeed, Rosenthal’s review suggests that inhibiting ET-1 can lower IOP and protect nerves (), although not all studies agree on ET-1’s pressure effects. In summary, too much ET-1 can both increase eye pressure slightly and pinch the eye’s blood supply, creating a “double hit” to the optic nerve. Evidence Linking ET-1 to Glaucoma Damage Many clinical studies find that ET-1 levels are higher in glaucoma. For example, a recent meta-analysis pooled data from over 1,000 glaucoma patients and healthy people. It found that plasma ET-1 was significantly higher in patients with primary open-angle, normal-tension, and angl Support the show

    12 min
  3. Substance P, Pain, and Neuroinflammation in Glaucoma

    6D AGO

    Substance P, Pain, and Neuroinflammation in Glaucoma

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/substance-p-pain-and-neuroinflammation-in-glaucoma Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Substance P, Pain, and Neuroinflammation in Glaucoma Glaucoma is a chronic eye disease that damages the optic nerve and can lead to vision loss. Many people with glaucoma also suffer from ocular surface discomfort – redness, burning, or dryness of the eye – especially if they use eye drops or have surgery. These symptoms are not only uncomfortable, but they can make it harder to stick to glaucoma treatment. Researchers have discovered that Substance P – a small protein (neuropeptide) released by nerve endings – plays a key role in eye pain and inflammation. Understanding how Substance P works may help us treat these symptoms. This article explains Substance P’s role in eye inflammation and pain, why that matters for glaucoma patients, and what studies tell us about drugs that block this pathway. Importantly, we distinguish easing symptoms (like dryness or pain relief) from protecting vision (slowing the nerve damage in glaucoma). Substance P and Neuroinflammation Substance P (SP) is a signaling molecule made by nerve cells. When nerves are irritated or injured, they release Substance P into the surrounding tissue. Substance P then binds to its receptor (called the neurokinin-1 receptor, or NK1R) on nearby cells. This triggers several effects: blood vessels in the tissue expand and become leaky, immune cells (like white blood cells) are recruited, and inflammatory chemicals (cytokines) are released (). In simple terms, Substance P tells the body, “Something’s wrong here – send help!” This process is called neurogenic inflammation. It helps fight infection or heal damage, but it also causes redness, swelling, and pain. For example, in the cornea (the clear front of the eye), Substance P causes blood vessels to dilate and immune cells to come in (). It also directly amplifies pain signals by acting on nerve fibers (Aδ and C fibers) that carry pain to the brain (). Because the cornea is one of the most heavily-innervated tissues in the body, it can produce and respond to a lot of Substance P () (). Normally, a small amount of SP helps regulate tear production and blink reflexes (). But after injury or chronic irritation (such as allergic or dry eye), SP levels can surge. High SP can make the cornea and conjunctiva (the white part of the eye) much more sensitive and inflamed. In experiments, blocking SP’s action strongly reduces inflammation: nerves that lack the SP receptor show fewer immune cells arrive, and mice missing SP themselves have less swelling () (). In other words, Substance P turns up the inflammation—and pain—in the eye. Why Substance P Matters for Glaucoma and Ocular Discomfort Glaucoma itself is characterized by loss of retinal ganglion cells (RGCs) in the back of the eye (the retina). However, many people with glaucoma experience ocular surface symptoms unrelated to vision: dryness, burning, soreness, or red eyes. These often come from eye drop preservatives or inflammation from surgeries, and they can involve Substance P. For example, irritating drops or foreign substances on the eye surface make corneal nerves release more SP (), which then increases inflammation and pain. Studies show that when the ocular surface is inflamed, trigeminal nerves (the ones sensing the eye) begin to express much more Substance P () (). This creates a vicious cycle Support the show

    17 min
  4. GLP-1 Peptides and Glaucoma Risk: What We Know and What to Watch

    APR 24

    GLP-1 Peptides and Glaucoma Risk: What We Know and What to Watch

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/glp-1-peptides-and-glaucoma-risk-what-we-know-and-what-to-watch Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Introduction GLP-1 receptor agonists (glucagon-like peptide-1 analogs) are a class of medicines originally developed to treat type 2 diabetes. By mimicking a natural gut hormone (GLP-1), drugs like semaglutide (Ozempic®, Wegovy®) and liraglutide (Victoza®, Saxenda®) help lower blood sugar and often cause weight loss 7{reference-type="ref"}. They are now used by millions of patients worldwide for diabetes and obesity. Interestingly, recent studies have observed that people taking these GLP-1 medicines seem to develop glaucoma – an eye disease that damages the optic nerve – less often than expected. In this article, we explain what GLP-1 agonists are, summarize the human evidence about glaucoma risk, describe how they might protect the eye, and discuss what kind of proof (randomized trials) is still needed. We also cover safety and regulatory issues. What Are GLP-1 Receptor Agonists? GLP-1 (glucagon-like peptide-1) is a natural hormone that helps the body release insulin and control appetite after eating. GLP-1 receptor agonists are medicines designed to act like GLP-1. Besides semaglutide and liraglutide, other examples include exenatide (Byetta®) and dulaglutide (Trulicity®). These drugs improve glycemic control (lower blood sugar) and often promote significant weight loss () (). Some newer GLP-1 agonists even come in pill form (e.g. oral semaglutide) (). Because they have “pleiotropic” effects, they also protect blood vessels and reduce inflammation in various parts of the body (). For instance, research in animals and humans has found that GLP-1 agonists improve heart and kidney health in diabetes (). GLP-1 RAs and the Eye GLP-1 receptors are present in many eye tissues, including nerve cells and blood vessel cells in the retina (). Laboratory studies show that activating these receptors can have powerful effects in the eye. GLP-1 drugs have anti-inflammatory, antioxidant, and neuroprotective actions in the retina (). For example, one experimental GLP-1 agonist (called NLY01) reduced damaging inflammation and prevented retinal ganglion cell death in a mouse model of glaucoma (). Another line of research found that GLP-1 analogs stabilize small blood vessels and the blood–retina barrier (the tight layer that protects the eye) (). In short, GLP-1 RAs have been shown to block multiple harmful processes in the eye – inflammation, oxidative stress, and nerve-cell damage – that are linked to glaucoma and other eye diseases () (). These findings have raised the idea that GLP-1 drugs might protect vision independently of their blood-sugar effects. Observational Evidence: Lower Glaucoma Rates Among GLP-1 Users? Several recent observational studies (looking at real-world patient data) have noted that people taking GLP-1 RAs develop glaucoma less often than similar patients who do not take them. For example, a U.S. insurance claims study compared about 1,961 new users of GLP-1 RAs to over 4,300 matched diabetic patients on other medications. After balancing the groups for age, gender, and diabetes control, the GLP-1 group had only 10 new cases of glaucoma (0.51%) versus 58 cases (1.33%) in controls. Statistically, this corresponded to a 44% lower hazard of glaucoma in the GLP-1 users (adjusted hazard ratio 0.56, 9 Support the show

    18 min
  5. Nerve Growth Factor–Based Peptides and Optic Nerve Protection

    APR 23

    Nerve Growth Factor–Based Peptides and Optic Nerve Protection

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/nerve-growth-factor-based-peptides-and-optic-nerve-protection Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Introduction Glaucoma is a common cause of vision loss that happens when the retinal ganglion cells (RGCs) – the nerve cells connecting the eye to the brain – gradually die. As one review notes, glaucoma is “characterized by RGC degeneration and loss of visual field” (pmc.ncbi.nlm.nih.gov). In other words, patients slowly lose side vision and eventually central vision. Current glaucoma medicines all lower eye pressure, but doctors are actively looking for ways to protect the optic nerve cells directly. One idea is to use nerve growth factor (NGF), a natural protein that helps nerves survive and grow. NGF is like a fertilizer for certain nerve cells (pmc.ncbi.nlm.nih.gov). In healthy eyes it supports RGC survival – in glaucoma, NGF levels may drop, so adding extra NGF might slow RGC loss. NGF and Neuroprotection NGF is a small protein (a neurotrophin) that binds to receptors on neurons and tells them “grow and live.” Animal and lab studies show NGF “plays a crucial role in neuronal survival, differentiation, and growth” (pmc.ncbi.nlm.nih.gov). In the eye, retinal ganglion cells have NGF receptors, meaning they can respond when NGF is present. The idea is that supplying more NGF could neuroprotect these cells. In other words, NGF might block the cell-death signals in glaucoma and keep RGCs alive longer. ... Continue reading at https://visualfieldtest.com/en/nerve-growth-factor-based-peptides-and-optic-nerve-protection Support the show

    12 min
  6. Heat shock protein-derived peptides and autoimmunity in glaucoma

    APR 22

    Heat shock protein-derived peptides and autoimmunity in glaucoma

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/heat-shock-protein-derived-peptides-and-autoimmunity-in-glaucoma Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Heat Shock Proteins and Immune Responses in Glaucoma Glaucoma is a leading cause of irreversible vision loss, affecting tens of millions of people worldwide (). Normally, glaucoma is linked to high eye pressure, but many patients – especially those with normal-tension glaucoma – have nerve damage despite normal pressure. This has led researchers to look beyond pressure and investigate the immune system’s role. In particular, eye experts have focused on heat shock proteins (HSPs), which are stress-related proteins that help keep nerve cells alive. Under some conditions these HSPs themselves may become targets of the immune system, contributing to nerve damage (). Evidence suggests that T cells (a type of white blood cell) reacting against HSPs can harm the optic nerve. For example, patient studies have found abnormally high levels of antibodies (proteins made by immune B cells) against HSPs in many glaucoma patients. In fact, multiple studies report that glaucoma patients often have elevated serum autoantibodies to HSP27 and HSP60, two common HSPs () (). In the lab, adding these patient antibodies to retinal cells can trigger cell death (), suggesting they are not just markers but may be damaging. In eye fluid (aqueous humor), glaucoma patients also show unique autoantibody “fingerprints,” including unusually high anti–HSP27 levels compared to healthy controls (). Taken together, these human findings point to an autoimmune tendency against HSPs in glaucoma. Evidence from Animal Models Studies in animals strongly support the idea that HSP-specific immune reactions can cause glaucoma-like damage. In classic experiments, scientists immunized healthy rats with HSP-derived peptides (for example, pieces of HSP27 or HSP60). Remarkably, these rats later developed nerve damage very similar to glaucoma () (). For instance, Wax and colleagues (2008) found that rats given HSP27 or HSP60 peptides lost large numbers of retinal ganglion cells (RGCs) – the neurons that form the optic nerve – and their axons in a pattern that closely mimics human glaucoma (). This damage occurred even though eye pressure stayed normal. Another group confirmed that immunizing rats with an optic-nerve extract (which contains many antigens, including HSPs) similarly caused RGC death and optic nerve thinning (). Importantly, these models also showed earlier immune changes: T cells infiltrated the retina days after immunization, and support cells (microglia) became activated, long before the neurons started dying () (). These animal experiments provide direct proof that an HSP-driven immune response can cause glaucoma-like neurodegeneration. Autoantibody Profiles in Patients Studies of glaucoma patients have found immune “signatures” consistent with HSP involvement. Many patients (especially with normal-tension glaucoma) carry autoantibodies against retina and optic nerve proteins, including HSPs () (). For example, researchers have detected antibodies to HSP27 and HSP60 in the blood of these patients (). In postmortem analyses, donor retinas from glaucoma patients showed antibody binding to HSP27 and HSP60 (). Laboratory tests imply these antibodies could be harmful: when anti-HSP27 antibodies from patients are applied to living retinal cells, Support the show

    12 min
  7. Endothelin pathway peptides and optic nerve head ischemia in glaucoma

    APR 21

    Endothelin pathway peptides and optic nerve head ischemia in glaucoma

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/endothelin-pathway-peptides-and-optic-nerve-head-ischemia-in-glaucoma Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Endothelin-1 and Glaucoma: Blood Flow, Astrocytes, and Therapy Endothelin-1 (ET-1) is a very strong vasoconstrictor (makes blood vessels tighten) found naturally in the body. In the eye, ET-1 levels and signaling have been linked to damage in glaucoma, a disease of the optic nerve. Glaucoma often involves high intraocular pressure (IOP), but other factors – especially reduced blood flow and oxygen (ischemia) at the optic nerve head – can contribute. ET-1 can narrow small blood vessels around the optic nerve and in the retina, leading to poor oxygen supply. It also affects astrocytes, the support cells of the optic nerve, which can become overactive when stressed. In this article, we explain how ET-1 and its receptors (called ETA and ETB) are involved in glaucoma, how ET-1 interacts with nitric oxide (a blood‐vessel relaxer), evidence that ET-1 levels are higher in glaucoma patients, and finally how blocking ET-1 receptors might help protect the eye (along with the challenges of such treatments). How ET-1 Affects Eye Blood Flow ET-1 is produced by many eye tissues (retina, ciliary body, trabecular meshwork, etc.). It normally helps regulate blood flow and aqueous humor outflow. However, high ET-1 causes excessive vasoconstriction. For example, human lab studies found that injecting ET-1 into the eye rapidly decreases blood flow in the retina and optic nerve head (). Blood vessel narrowing leads to local ischemia (low oxygen), which can injure retinal ganglion cell (RGC) axons. ET-1 even has a direct toxic effect: it can trigger RGCs to undergo apoptosis (cell death) () (). Astrocytes – star-shaped glial cells in the optic nerve – also respond to ET-1. When ET-1 is high, astrocytes can multiply and change shape (a process called astrogliosis). This reactive gliosis can further harm the optic nerve environment. In lab cultures, ET-1 causes optic nerve astrocytes to proliferate, and this effect is blocked by either ETA or ETB receptor inhibitors (). In glaucomatous optic nerves (from humans and animals), researchers have observed more astrocyte proliferation and GFAP (a stress protein) when ET-1 is elevated (). Nitric Oxide and ET-1: Balancing Vessel Tone In healthy eyes, nitric oxide (NO) and ET-1 balance each other. NO is a vasodilator (it widens vessels), whereas ET-1 constricts them. Endothelial cells lining blood vessels release NO under normal conditions, relaxing the vessel walls (). Any disturbance in this balance – for example, too much ET-1 or too little NO – can impair blood flow. In the human ophthalmic (eye) artery, experiments showed that blocking NO causes vessels to constrict and that adding ET-1 causes strong constriction (). Thus, ET-1’s vasoconstriction can overcome NO’s dilating effect. Indeed, in glaucoma, impaired NO production (often due to endothelial dysfunction) is thought to worsen ET-1–induced ischemia. In some studies, giving ET-1 to people or animals reduced NO-mediated blood flow significantly, and an ETA-blocker (like BQ-123) could prevent that reduction (). This cross-talk means that high ET-1 disrupts the normal NO-driven relaxation, promoting a harmful cycle of poor blood supply. ET-1 Receptors: ETA and ETB Signaling ET-1 works by binding two main receptors on cells, Support the show

    14 min
  8. MOTS-c and Glaucoma: A Mitochondrial Signal With Bigger Implications Than Eye Pressure?

    APR 20

    MOTS-c and Glaucoma: A Mitochondrial Signal With Bigger Implications Than Eye Pressure?

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/mots-c-and-glaucoma-a-mitochondrial-signal-with-bigger-implications-than-eye-pressure Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: MOTS-c and Glaucoma: A Mitochondrial Signal With Bigger Implications Than Eye Pressure? Glaucoma is an optic nerve disease often linked to high eye pressure, but it involves many cellular stress pathways. MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a tiny peptide made by mitochondria that helps cells cope with stress. Could it influence glaucoma progression or vulnerability beyond just controlling pressure? This article examines the mechanistic links between MOTS-c and glaucoma. We separate established facts from indirect clues and educated speculation. Every big claim is cited to the literature. What MOTS-c Is In 2015, researchers discovered MOTS-c – a 16-amino-acid peptide encoded in mitochondrial DNA (mtDNA) (). It is produced from a short open reading frame in the mitochondrial 12S rRNA gene (). MOTS-c levels rise in response to stress or exercise and decline with age (). Under stress, MOTS-c moves from the mitochondria to the cell nucleus, where it helps activate antioxidant and stress-defense genes (). MOTS-c acts mainly through cellular energy sensors. It boosts the AMP-activated protein kinase (AMPK) pathway by diverting substrates toward AICAR production, mimicking a fasting/exercise signal () (). AMPK is a key regulator of energy balance in cells. When AMPK is activated, it in turn can increase PGC-1α, a master regulator of mitochondrial function (). Thus, MOTS-c indirectly drives cells to make more energy and repair mitochondria. MOTS-c also influences inflammation and oxidative stress. In cell studies, treating stressed cells with MOTS-c increased AMPK and PGC-1α levels and lowered reactive oxygen species (ROS) and inflammatory signals (). Specifically, MOTS-c reduced activation of NF-κB (a protein that drives inflammation) and cut levels of pro-inflammatory cytokines (like TNF-α, IL-1β, IL-6) while boosting anti-inflammatory IL-10 (). It can also activate NRF2 pathways, which turn on antioxidant defenses () (). In simpler terms, MOTS-c is a stress-adaptive hormone made by mitochondria. It helps cells cope with metabolic and oxidative challenges by fueling energy production and calming inflammation () (). It is being studied for benefits in diabetes, neurodegeneration, and aging-related conditions () (). However, its role in eye diseases (especially glaucoma) is not established. Why Glaucoma Might Intersect with MOTS-c Glaucoma damages the optic nerve and kills retinal ganglion cells (RGCs). Classic glaucoma causes are high intraocular pressure (IOP) and aging, but pressure-independent factors also play a major role. Key features of glaucoma biology may interact with what MOTS-c does: Retinal Ganglion Cell Energy Needs: RGCs have high metabolic demand. Their unmyelinated axons use many ATP-driven ion pumps and are packed with mitochondria (). These cells depend heavily on oxidative phosphorylation (OXPHOS) for energy (). If mitochondria falter, RGCs quickly suffer. In principle, MOTS-c’s ability to boost mitochondrial energy production could protect such high-demand neurons. (This is speculative: RGC-specific data on MOTS-c are lacking.) Mitochondrial Dysfunction in Glaucoma: A growing body of evidence implicates mitochondrial failure i Support the show

    21 min
See All (164)

About

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

Information

You Might Also Like